People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Diffusion Pharmaceuticals Inc. | — | Pharmaceuticals | Series C | $140.0M | $26.3M | 2014 |
Craig Abolin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Craig Abolin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 1 | 14 |
| Sol Barer | 1 | 6 |
| William Kelly | 1 | 5 |
| PAUL FELLER | 1 | 4 |
| Nelson Stacks | 1 | 3 |
| Rex Bright | 1 | 3 |
| Ben L. Shealy | 1 | 2 |
| David G. Kalergis | 1 | 2 |
| John L. Gainer | 1 | 2 |
| Mark T. GIles | 1 | 2 |
| Robert W. Adams | 1 | 2 |
| David R. Jones | 1 | 2 |
| Stephen Simes | 1 | 2 |
| David Sherris | 1 | 2 |
| John Moynahan | 1 | 1 |
| Glenn Golenberg | 1 | 1 |
| Mike Dunleavy, Sr. | 1 | 1 |
| Thomas S. Byrne | 1 | 1 |
| William K. Hornung | 1 | 1 |
| Timothy Boris | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.